VIP (Vasoactive Intestinal Peptide): Research Overview

• VIP is a 28-amino-acid neuropeptide first identified in the early 1970s.
• Research links VIP to immune balance, gut barrier support, vasodilation, and secretory control.
• Preclinical studies suggest VIP can reduce inflammatory injury in models of arthritis and colitis.
• VIP also has research interest in glucose homeostasis, but its short half-life limits clinical use.

What VIP Is

Vasoactive Intestinal Peptide, or VIP, is a 28-amino-acid neuropeptide. It is made in more than one tissue and acts as a signaling molecule across systems, not just in one organ. The research describes it as part of the neuro-immune-gut axis, where it helps coordinate how tissues respond to stress, inflammation, and injury.

VIP was first identified in the early 1970s. Since then, research has expanded from basic physiology into immune control, gut barrier function, vascular tone, secretion, and metabolic regulation. In the sources provided, VIP is repeatedly described as a broad regulator rather than a single-purpose peptide.

How researchers frame it

One review describes VIP as a “master regulator” because it acts through widely distributed receptors and affects several body systems at once. That broad reach is the reason VIP appears in research on inflammation, intestinal integrity, neurovascular function, and glucose control. It is also why VIP has attracted interest in both integrative medicine and mainstream physiology.

Core Research Areas

Immune modulation

A major theme in VIP research is immune balance. The supplied material describes VIP as strongly anti-inflammatory. It is reported to suppress pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-12, while promoting anti-inflammatory signals such as IL-10. It is also linked to increased regulatory T-cell activity and reduced Th1 and Th17 responses.

That pattern matters because many inflammatory diseases are driven by overactive immune signaling. In animal research, VIP has been associated with downregulation of inflammatory and autoimmune processes. In one arthritis model, VIP reduced disease severity, lowered inflammatory infiltrates, and reduced cartilage and bone damage.

Gut barrier and mucosal protection

VIP also appears in research on intestinal health. A Nature Portfolio summary describes VIP as contributing to epithelial barrier integrity, mucosal immune control, and gut microbial composition in inflammatory bowel disease. When VIP synthesis or signaling is disrupted, the summary links that to barrier dysfunction, higher inflammatory cytokine release, and microbial imbalance.

In experimental colitis models, VIP deficiency has been associated with worse mucosal injury. The same summary notes that exogenous VIP can rescue barrier integrity and reduce inflammatory damage in those settings. This makes VIP an active area of interest for researchers studying ulcerative colitis and Crohn’s disease.

Vascular and secretory effects

VIP is also described as vasodilatory and secretomotor. That means it can influence blood vessel tone and glandular secretion. These effects help explain why VIP appears in research that spans the gut, lungs, blood vessels, and nervous system. Its biology is not limited to digestion even though the name includes “intestinal.”

Glucose homeostasis

Another research direction is glucose control. A 2022 review in Frontiers says VIP can stimulate glucose-dependent insulin secretion, especially through VPAC2 receptors. The same review says VIP can also promote pancreatic islet beta-cell proliferation through the FOXM1 pathway. In that context, VIP is being studied as part of the search for treatments that support insulin secretion without causing hypoglycemia.

The review also points out a key limitation: VIP has a short half-life and wide distribution in the human body, which makes direct clinical use difficult. That is one reason researchers have explored VPAC2-selective agonists as a more targeted approach.

What the Preclinical Data Shows

Arthritis models

One of the clearest examples in the provided research comes from a mouse model of collagen-induced arthritis. The Johns Hopkins Arthritis summary reports that VIP treatment delayed disease onset, lowered incidence, and reduced severity compared with placebo. Histology showed less inflammatory infiltrate, less pannus formation, and less cartilage and bone destruction.

That same summary describes several immune changes tied to the benefit: reduced T-cell clonal expansion, lower Th1 cytokines such as interferon-gamma, increased Th2 cytokines such as IL-4, reduced tumor necrosis factor and interleukin-1, and increased interleukin-10 and interleukin-1 receptor antagonist. The study supports a broad immune-modulating role in animal arthritis, not a narrow one.

Inflammatory bowel disease models

The Nature Portfolio summary reports that VIP deficiency worsens colitis in mouse models, with greater weight loss, more disease activity, and more histologic damage. It also says low VIP levels correlate with impaired mucosal protection and stronger inflammatory signaling. In those models, restoring VIP expression reduced disease severity. That points to a protective role for endogenous VIP in the colon.

Feeding and body composition

VIP is also studied in metabolism and body regulation. One PMC study examined VIP-deficient mice to assess feeding behavior and body composition. The setup included weekly body composition measurements by nuclear magnetic resonance and food intake monitoring with BioDAQ cages. This line of work shows that VIP is relevant not only to inflammation, but also to appetite and energy balance.

Clinical Interest and Limits

Why researchers are interested

VIP is appealing because it touches several high-value physiology targets at once: immune tone, mucosal health, vascular regulation, and glucose signaling. That makes it interesting in inflammatory disease, metabolic disease, and gut disorders. The research also suggests that VIP is not just a marker of disease activity. In some models, changing VIP levels changes the disease process itself.

What limits use

The main limitation in the supplied research is pharmacologic. VIP has a short half-life and broad distribution, which makes it hard to use directly as a drug. That is why some researchers focus on receptor-selective agonists, especially VPAC2-selective compounds, rather than VIP itself.

Another limit is evidence quality. Much of the supplied material comes from reviews, summaries, and animal studies. That means the findings are useful for understanding mechanism, but they do not prove that the same results will happen in people.

What not to assume

It is not supported by the supplied research to treat VIP as a proven therapy for human disease. The current material supports biologic plausibility, preclinical benefit, and ongoing research interest. It does not establish routine clinical use for arthritis, colitis, diabetes, or other conditions.

Related Peptide Context

VIP often appears in the same broad peptide discussions as other endogenous signaling molecules such as oxytocin. That does not mean the peptides do the same thing. It means modern peptide research often looks at small, body-made signals that can affect the brain, immune system, and peripheral organs at the same time.

For VIP, that systems-level role is central. The research consistently places it at the intersection of inflammation control, gut protection, and autonomic regulation.

FAQ

What is VIP in simple terms?

VIP is a 28-amino-acid peptide made by the body. It sends signals between tissues and helps regulate inflammation, vascular tone, secretion, and gut function.

Why is VIP called a “master regulator”?

Researchers use that label because VIP acts through widely distributed receptors and affects several systems at once, especially immune balance, gut barrier integrity, and neurovascular function.

What does VIP do in inflammation?

The supplied research says VIP lowers pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-12, while increasing anti-inflammatory signals like IL-10. It is also linked to regulatory T-cell activity and lower Th1 and Th17 responses.

Has VIP been studied in disease models?

Yes. The provided research includes animal studies in arthritis, colitis, and feeding/body composition. In those models, VIP was associated with lower inflammatory damage and improved tissue protection.

Is VIP already used as a standard treatment?

No standard use is supported by the supplied material. The research shows interest and preclinical promise, but also notes major limits such as VIP’s short half-life and wide distribution in the body.